引用次数
引用: 52,971
H-指数: 87
I10-指数 : 259
出版物: 613
In Vivo Investigation of Estrogen Regulation of Adrenal and Renal Angiotensin (AT1) Receptor Expression by PET
Hayden T. Ravert , Paige Rauseo , William B. Mathews , Maria E. Fabucci
The Journal of Nuclear Medicine 45 ( 1) 94 -100
42
2004
Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC)
Athanasios Kotsakis , Taofeek K. Owonikoko
The Open Lung Cancer Journal 3 ( 1)
3
2010
Lung cancer in the elderly: what's age got to do with it?
Fadlo R. Khuri , Taofeek K. Owonikoko , Suresh S. Ramalingam
Oncology 24 ( 12)
2
2010
Thriving where others have faltered—a critical appraisal of the role of patient factors versus treatment effect in JCOG0605 trial in relapsed small cell lung cancer
Taofeek K. Owonikoko , Nikita T. Patel
Translational cancer research 5 ( 6)
2016
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Roy S. Herbst , David R. Gandara , Thomas E. Stinchcombe , Vassiliki Papadimitrakopoulou
Clinical Lung Cancer
11
2021
Phase I expansion study of P-cadherin-targeted 90Y-FF-21101 antibody in advanced chemorefractory colorectal and pancreatic-biliary cancers.
Devalingam Mahalingam , Vivek Subbiah , Taofeek K Owonikoko , Susanna Varkey Ulahannan
Journal of Clinical Oncology 39 78 -78
2021
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Robert M. Jotte , Taofeek K. Owonikoko , Jessica A. Sorrentino , Patrick J. Roberts
Cancer Chemotherapy and Pharmacology 87 ( 5) 689 -700
2021
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
Naomi Kiyota , Corina E. Dutcus , Taofeek K. Owonikoko , Ana O. Hoff
European Journal of Cancer 147 51 -57
1
2021
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
Conor E Steuer , Christopher C Griffith , Sreenivas Nannapaneni , Mihir R Patel
Molecular Cancer Therapeutics 17 ( 3) 710 -716
16
2018
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature
Rathi N Pillai , Madhusmita Behera , Taofeek K Owonikoko , Alice O Kamphorst
Cancer 124 ( 2) 271 -277
147
2018
Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
Richard J. Cassidy , Xinyan Zhang , Jeffrey M. Switchenko , Pretesh R. Patel
Cancer 124 ( 4) 775 -784
11
2018
Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy
Richard J. Cassidy , Xinyan Zhang , Pretesh R. Patel , Joseph W. Shelton
Cancer 123 ( 19) 3681 -3690
21
2017
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Kushal B Naik , Yuan Liu , Michael Goodman , Theresa W Gillespie
Cancer 123 ( 18) 3476 -3485
20
2017
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Robert H. Press , Chao Zhang , Richard J. Cassidy , Matthew J. Ferris
Cancer 124 ( 17) 3586 -3595
1
2018
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy
Mehmet A. Bilen , Dylan J. Martini , Yuan Liu , Colleen Lewis
Cancer 125 ( 1) 127 -134
59
2019
The clinical conundrum of managing relapsed small cell lung cancer
Bassel Nazha , Taofeek K. Owonikoko
Cancer 125 ( 7) 1022 -1026
2019
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials
Dylan J. Martini , Meredith R. Kline , Yuan Liu , Julie M. Shabto
Cancer 126 ( 3) 575 -582
18
2020
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Yiting Li , Hongjing Zang , Guoqing Qian , Taofeek K. Owonikoko
Cancer 126 ( 6) 1339 -1350
11
2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Hongjing Zang , Guoqing Qian , Dan Zong , Songqing Fan
Cancer 126 ( 9) 2024 -2033
31
2020
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q.
Brian Pedro , Manali Rupji , Bhakti Dwivedi , Jeanne Kowalski
Cancer 126 ( 13) 3140 -3150
1
2020
Fadlo R. Khuri nabil saba Walter Curran Dong Moon Shin, MD, FACP Jonathan J Beitler Michael R. Rossi, Ph.D. J. Trad Wadsworth, MD, MBA, FACS Camille Ragin Suzanne Dahlberg Maohua Xie John Kauh Edmund K Waller Mourad Tighiouart Paul W. Doetsch Dana Nickleach Wei Zhou William A. Hall, MD Adebowale Akintayo Roshan Prabhu, MD, MSc